薬の用量の違いによるNN0519-0130の2型糖尿病患者の血糖降下効果を比較した研究研究
2型糖尿病の参加者における週1回のNNC0519-0130の安全性と有効性の調査 - 用量調査研究
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Chula Vista、California、アメリカ、91911
- Velocity Clin Res-Chula Vista
-
Fresno、California、アメリカ、93720
- Valley Research
-
Inglewood、California、アメリカ、90301
- 310 Clinical Research
-
La Mesa、California、アメリカ、91942
- Velocity Clin Res San Diego
-
Lancaster、California、アメリカ、93534
- First Valley Med Grp Lancaster
-
Lomita、California、アメリカ、90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos、California、アメリカ、90720
- Pacific Clinical Studies
-
Los Angeles、California、アメリカ、90057
- Velocity Clinical Research Westlake
-
Montclair、California、アメリカ、91763
- Catalina Research Institute, LLC
-
San Diego、California、アメリカ、92123
- Artemis Insitute for Clin Res
-
Toluca Lake、California、アメリカ、91602
- Med Partners, Inc.
-
Torrance、California、アメリカ、90505
- UCLA Health Southbay Endocrine
-
Tustin、California、アメリカ、92780
- University Clin Investigators
-
Walnut Creek、California、アメリカ、94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater、Florida、アメリカ、33756
- Innovative Research of W Florida Inc.
-
Clearwater、Florida、アメリカ、33756
- Innovative Research of W FL
-
Miami、Florida、アメリカ、33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus、Georgia、アメリカ、31904
- Centricity Research
-
-
Idaho
-
Blackfoot、Idaho、アメリカ、83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria、Illinois、アメリカ、61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa
-
-
Maryland
-
Columbia、Maryland、アメリカ、21045
- Centennial Medical Group
-
Oxon Hill、Maryland、アメリカ、20745
- MD Medical Research
-
Rockville、Maryland、アメリカ、20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield、Missouri、アメリカ、65807
- Clinvest Research
-
-
Montana
-
Butte、Montana、アメリカ、59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89148
- Palm Research Center Inc-Vegas
-
Las Vegas、Nevada、アメリカ、89109
- Excel Clinical Network
-
-
New York
-
Binghamton、New York、アメリカ、13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro、North Carolina、アメリカ、27408
- PharmQuest Life Sciences LLC
-
Wilmington、North Carolina、アメリカ、28401
- Accellacare Wilmington
-
-
Ohio
-
Canton、Ohio、アメリカ、44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati、Ohio、アメリカ、45242
- Velocity Clin Res_Cincinnati
-
Cincinnati、Ohio、アメリカ、45246
- Velocity Clinical Research Springdale
-
Dayton、Ohio、アメリカ、45439
- Providence Health Partners Ctr
-
Maumee、Ohio、アメリカ、43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass、Oregon、アメリカ、97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19114
- Tristar Clin Investigations, PC
-
Pittsburgh、Pennsylvania、アメリカ、15243
- Preferred Primary Care Physicians Inc.
-
Uniontown、Pennsylvania、アメリカ、15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene、Texas、アメリカ、79606
- Velocity Clinical Research Abilene
-
Austin、Texas、アメリカ、78759
- Velocity Clin Res Austin
-
Dallas、Texas、アメリカ、75390
- UT Southwestern Med Center
-
Dallas、Texas、アメリカ、75230
- Velocity Clinical Res-Dallas
-
Dallas、Texas、アメリカ、75230
- Zenos Clinical research
-
Forney、Texas、アメリカ、75126
- Care United Research, LLC
-
Houston、Texas、アメリカ、77004
- Endocrine Associates Houston
-
Houston、Texas、アメリカ、77043
- Biopharma Informatic_Houston
-
Irving、Texas、アメリカ、75039
- Tekton Research
-
Lewisville、Texas、アメリカ、75057
- Epic Clinical Research
-
Shavano Park、Texas、アメリカ、78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke、Virginia、アメリカ、22015
- Burke Internal Medicine & Research
-
Newport News、Virginia、アメリカ、23606
- TPMG Clinical Research
-
-
-
-
-
Bengaluru、インド、560054
- MS Ramaiah
-
New Delhi、インド、110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore、Karnataka、インド、560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi、Kerala、インド、682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore、Madhya Pradesh、インド、452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai、Maharashtra、インド、400012
- Seth GS Medical College & KEM Hospital
-
Pune、Maharashtra、インド、411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore、Tamil Nadu、インド、632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad、Telangana、インド、500082
- Diabetes Research Center, Hyderabad
-
-
-
-
New South Wales
-
Campbelltown、New South Wales、オーストラリア、2560
- Campbelltown Hospital
-
Macquarie Park、New South Wales、オーストラリア、2109
- Macquarie University - Clinical Trials Unit
-
St Leonards、New South Wales、オーストラリア、2065
- Royal North Shore Hospital
-
Sydney、New South Wales、オーストラリア、2148
- Western Endocrine Blacktown
-
Sydney、New South Wales、オーストラリア、2148
- Roger Chih Yu Chen
-
Wollongong、New South Wales、オーストラリア、2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya、Queensland、オーストラリア、4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook、Queensland、オーストラリア、4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park、South Australia、オーストラリア、5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill、Victoria、オーストラリア、3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell、Victoria、オーストラリア、3124
- Emeritus Research Melbourne
-
Heidelberg Heights、Victoria、オーストラリア、3081
- Austin Health, Metabolic Disorders Centre
-
Parkville、Victoria、オーストラリア、3050
- The Royal Melbourne Hospital
-
Parkville、Victoria、オーストラリア、3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle、Western Australia、オーストラリア、6160
- Fremantle Hospital
-
-
-
-
-
Québec、カナダ、G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna、British Columbia、カナダ、V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond、British Columbia、カナダ、V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria、British Columbia、カナダ、V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton、New Brunswick、カナダ、E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie、Ontario、カナダ、L4N 7L3
- Centricity Research Barrie
-
Hamilton、Ontario、カナダ、L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia、Ontario、カナダ、N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto、Ontario、カナダ、M4G 3E8
- Centricity Research Toronto
-
Toronto、Ontario、カナダ、M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis、Quebec、カナダ、G6W 0M5
- Centricity Research Quebec City
-
Mirabel、Quebec、カナダ、J7J 2K8
- Centricity Research Mirabel
-
Montreal、Quebec、カナダ、H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent、Quebec、カナダ、H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
Free State
-
Bloemfontein、Free State、南アフリカ、9301
- Josha Research
-
-
Gauteng
-
Johannesburg、Gauteng、南アフリカ、2013
- Wits Bara Clinical Trial Site
-
Midrand、Gauteng、南アフリカ、1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban、KwaZulu-Natal、南アフリカ、4450
- Dr Pillay's Rooms
-
eMkhomazi、KwaZulu-Natal、南アフリカ、4170
- Dr T Padayachee
-
-
-
-
-
Chiba、日本、261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama、日本、340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo、日本、104-0031
- Fukuwa Clinic
-
Tokyo、日本、103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo、日本、104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul、韓国、03181
- Kangbuk Samsung Hospital
-
Seoul、韓国、02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si、Gyeonggi-do、韓国、13620
- Seoul National University Bundang Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
実験的:Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
プラセボコンパレーター:Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
アクティブコンパレータ:Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
時間枠:From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
時間枠:From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
時間枠:From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
時間枠:From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
時間枠:From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Clinical Transparency (dept. 2834)、Novo Nordisk A/S
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- NN9541-4945
- U1111-1291-9196 (その他の識別子:World Health Organization (WHO))
- jRCT2031230704 (レジストリ識別子:JRCT)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。